-
-
-
Loading
Loading
The agreement to restore calm is welcome. Pity it won’t last
Though aimed at shareholders, some of the costs fall on workers
Politicians are attacking IP protection, but shareholders are Big Pharma’s bigger headache
A gathering economic recovery shows it sometimes can